Trial Profile
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Eicosapentaenoic acid (Primary)
- Indications Familial adenomatous polyposis
- Focus Registrational; Therapeutic Use
- Acronyms EPA-Pol-04
- Sponsors SLA Pharma
- 20 Dec 2022 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 26 Oct 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 27 Aug 2022 This trial was completed in Netherlands, according to European Clinical Trials Database.